Hepatitis C Update
DOI:
https://doi.org/10.17140/lroj-2-e003Abstract
The pace of Hepatitis C Virus (HCV) drug development in recent years has accelerated dramatically. But, for patients to benefit from these impressive advances, practitioners (i.e. “us”) need to know the most recent and accurate data on the diagnosis and treatment.
References
AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguide-lines.org 2011; Accessed September 1, 2015.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2009; 49: 1335-1374.
Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10): 705-714. doi: 10.7326/0003-4819-144-10-200605160-00004
Soriano V, Perelson AS, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? Antimicrob Chemother. 2008; 62(1): 1-4. doi: 10.1093/jac/dkn175
Rousseau CM, Ioannou GN, Todd-Stenberg JA, et al. Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. Am J Public Health. 2008; 98(5): 846-882. doi: 10.2105/AJPH.2007.113225 Liver Res Open J Page e2
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Liver Research (LROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.